TOKYO, Jan 9, 2023 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. announced Eisai has submitted a supplemental Biologics License Application …
FDA Approves LEQEMBI (lecanemab-irmb) Under the Accelerated Approval Pathway for the Treatment of Alzheimer’s Disease
TOKYO and CAMBRIDGE, Mass., Jan 9, 2023 – (JCN Newswire via SEAPRWire.com) – Eisai Co., Ltd. and Biogen Inc. announced today that under the Accelerated …